ArticlePloS one2024
GFPrint™: A machine learning tool for transforming genetic data into clinical insights.
Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The increasing availability of massive genetic sequencing data in the clinical setting has triggered the need for appropriate tools to help fully exploit the wealth of information these data possess. GFPrint™ is a proprietary streaming algorithm designed to meet that need. By extracting the most relevant functional features, GFPrint™ transforms high-dimensional, noisy genetic sequencing data into an embedded representation, allowing unsupervised models to create data clusters that can be re-mapped to the original clinical information. Ultimately, this allows the identification of genes and pathways relevant to disease onset and progression. GFPrint™ has been tested and validated using two cancer genomic datasets publicly available. Analysis of the TCGA dataset has identified panels of genes whose mutations appear to negatively influence survival in non-metastatic colorectal cancer (15 genes), epidermoid non-small cell lung cancer (167 genes) and pheochromocytoma (313 genes) patients. Likewise, analysis of the Broad Institute dataset has identified 75 genes involved in pathways related to extracellular matrix reorganization whose mutations appear to dictate a worse prognosis for breast cancer patients. GFPrint™ is accessible through a secure web portal and can be used in any therapeutic area where the genetic profile of patients influences disease evolution.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.